OSTO:KARO (Sweden)
Business Description
Karo Pharma AB
NAICS : 325412
Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22
Compare
Compare
Traded in other countries / regions
KA6N.Germany
•
KARO.Sweden
•
0RAQ.UK
•
KARBF.USA
Description
Karo Pharma AB is a healthcare corporation. It is primarily engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of research and development for drug discovery. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 1.06 | |||||
| Debt-to-EBITDA | 44.66 | |||||
| Interest Coverage | 1.09 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.97 | |||||
| Beneish M-Score | -2.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5 | |||||
| 3-Year EBITDA Growth Rate | -9.5 | |||||
| 3-Year Book Growth Rate | 6.4 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.05 | |||||
| 9-Day RSI | 44.02 | |||||
| 14-Day RSI | 42.61 | |||||
| 6-1 Month Momentum % | -12.97 | |||||
| 12-1 Month Momentum % | -3.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.71 | |||||
| Quick Ratio | 1.82 | |||||
| Cash Ratio | 0.56 | |||||
| Days Inventory | 153.95 | |||||
| Days Sales Outstanding | 82.38 | |||||
| Days Payable | 53.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | -100 | |||||
| 3-Year Average Share Buyback Ratio | -10.2 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 57.62 | |||||
| Operating Margin % | 6.73 | |||||
| Net Margin % | -0.58 | |||||
| ROE % | -0.27 | |||||
| ROA % | -0.12 | |||||
| ROIC % | -1.71 | |||||
| ROC (Joel Greenblatt) % | 21.1 | |||||
| ROCE % | 1.75 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.85 | |||||
| PB Ratio | 1.67 | |||||
| Price-to-Operating-Cash-Flow | 21.38 | |||||
| EV-to-EBIT | 113.57 | |||||
| EV-to-EBITDA | 113.57 | |||||
| EV-to-Revenue | 7.5 | |||||
| EV-to-FCF | -59.51 | |||||
| Price-to-Projected-FCF | 2.87 | |||||
| Price-to-Median-PS-Value | 1.49 | |||||
| Earnings Yield (Greenblatt) % | 0.88 | |||||
| Forward Rate of Return (Yacktman) % | -23.15 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 2,961.453 | ||
| EPS (TTM) (kr) | -0.088 | ||
| Beta | 0.2 | ||
| Volatility % | 18.76 | ||
| 14-Day RSI | 42.61 | ||
| 14-Day ATR (kr) | 1.105759 | ||
| 20-Day SMA (kr) | 51.155 | ||
| 12-1 Month Momentum % | -3.33 | ||
| 52-Week Range (kr) | 49.25 - 64.63687 | ||
| Shares Outstanding (Mil) | 273.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Karo Pharma AB Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||